- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04059380
Evaluation of iMmune Function in Post-surgical and AuToimmune HYpoparathyroidism (EMPATHY) (EMPATHY)
Evaluation of iMmune Function in Post-surgical and AuToimmune HYpoparathyroidism: The EMPATHY Study
Study Overview
Status
Detailed Description
This is an observational pilot study for the evaluation of immune function, infectious diseases, psychometric status and quality of life in patients with hypoparathyroidism compared to healthy controls.
All patients with Hypoparathyroidism will be on established conventional therapy with calcium supplements and calcitriol. According to guidelines, possible confounding factors (i.e. Vitamin D, serum magnesium levels) will be evaluated at screening visit. Age-, sex- and BMI- matched healthy controls will be enrolled.
Patients and controls will undergo a screening visit (V0) and a baseline visit (V1) in the following month.
The primary outcome will be the immune profiling of patients with hypoparathyroidism compared to healthy controls by the quantification of peripheral blood mononuclear cells (PBMC) subpopulations assessed by flow cytometry.
Secondary Outcome Measures will be:
Functional evaluation of PBMC cytokine secretion assessed by flow cytometry
Evaluation of calcium signaling components expression compared to healthy controls
Evaluation of PTHR1 expression in immune cells compared to healthy controls
Evaluation of inflammatory cytokines production compared to healthy controls.
Evaluation of quality of life compared to healthy controls. Quality of life will be measured by Short Form (SF)-36-Item Health Survey total score, SF-36-Item Health Survey physical component summary score and SF-36-Item Health Survey mental component summary score.
Evaluation of infectious diseases frequencies and severity compared to healthy controls. Infectious diseases will be evaluated by an adaptation of Infectious Diseases Questionnaire (GNC).
Psychometric evaluation by self-administered questionnaires: Beck depression Index, Middlesex Hospital Questionnaire.
Sleep disturbances evaluation by The Pittsburgh Sleep Quality Index (PSQI) self reported questionnaire.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Rome, Italy, 00161
- Department of Experimental Medicine, "Sapienza" University of Rome
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Previously diagnosed (at least 6 months before enrolment) hypoparathyroidism which required daily calcium (≥1000mg/die) and calcitriol therapy;
- Signed informed consent to participate in the study.
Exclusion Criteria:
- Transient hypoparathyroidism;
- History of neoplasms, radiotherapy or chemotherapy in the last 5 years;
- Clinical or laboratory signs of significant respiratory, hepatobiliary, or pancreatic disease;
- Severe infections, surgery, trauma requiring hospitalization within 3 months before enrolment;
- Severe chronic kidney disease (stage 4-5);
- Any active blood or rheumatic disorders in the last 5 years
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
---|
Patients with Hypoparathyroidism
Patients with Post-Surgical or Autoimmune Chronic Hypoparathyroidism requiring daily calcium and calcitriol therapy
|
Healthy Controls
Age-, sex- and BMI- matched patients referring to our center for diagnostic procedures not affected by hypoparathyroidism
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peripheral Blood Mononuclear Cells
Time Frame: baseline
|
Number of cells (number per mm3) of peripheral blood mononuclear cell subpopulations
|
baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cell-specific Inflammatory Cytokine expression
Time Frame: baseline
|
Cell-specific Cytokine expression by flow cytometry - Composite outcome measure of Tumor Necrosis Factor α (TNFα), Transforming Growth Factor-β (TGF-β) and Interferon-γ (IFN-γ) intracellular concentration
|
baseline
|
PTHR1 expression
Time Frame: baseline
|
Measurement of PTHR1 expression by Prime Flow RNA assay
|
baseline
|
Inflammatory cytokines levels
Time Frame: baseline
|
Chemiluminescence measurement of TNFα, TGF-β and IFN-γ serum concentrations.
|
baseline
|
Infectious diseases frequency and severity
Time Frame: baseline
|
Frequencies and severity of infectious diseases will be evaluated by modified Infectious Diseases Questionnaire (GNC). This questionnaire includes questions on infectious diseases of upper and lower respiratory tract, gastrointestinal tract, skin and urogenital tract contracted during the previous 12 months. Questions investigate on the number and duration of infections, necessity of antibiotic or antifungal therapy, hospital stay and days of absence from work. Final score represents the frequency of infections. Moreover, some questions investigate possible susceptible or protective factors for infectious diseases: vaccinations, use of corticosteroids, concomitant diseases, previous appendectomy, tonsillectomy, adenoidectomy, splenectomy or thymectomy. |
baseline
|
Calcium Signaling evaluation
Time Frame: baseline
|
Composite outcome consisting of simultaneous measurement of calcium channels and related proteins: Cav1, Calcium Release Activating Channel, Stromal Interaction Molecule 1 (STIM1), Calcium release-activated calcium modulator 1 (encoded by Orai1 gene), Inositol trisphosphate receptor, Nuclear factor of activated T-cells, Calcineurin and Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B cells (NF-kB) expression evaluated by Prime Polymerase chain reaction
|
baseline
|
Quality of life: SF-36-Item Health Survey questionnaire
Time Frame: baseline
|
Quality of life will be evaluated by the Physical Component score and the Mental Component score of the self-administered questionnaire SF-36-Item Health Survey questionnaire. This questionnaire measures eight scales: physical functioning, role physical, bodily pain, general health (physical component) and vitality, social functioning, role emotional, mental health (mental component). Interpretation of the score will be the following: at each item of the questionnaire corresponds a percentage value (from 0% to 100%). The average of the single items constitutes the scale total percentage (from 0% to 100%); missing data are not considered during calculation. High score defines a more favorable health state. |
baseline
|
Psychometric evaluation
Time Frame: baseline
|
Psychometric evaluation will be assessed by the scores of two self-administered questionnaires: Beck depression Index and Middlesex Hospital Questionnaire. Beck depression Index is a 21-item measure of depressive symptoms. Each answer is scored on a scale value (from 0 to 3 points). The global score is obtained adding all single scores, with a range of 0-63. Higher score constitutes worse burden of symptoms (0-13: minimal depression, 14-19: mild depression, 20-28: moderate depression, 29-63: severe depression) Middlesex Hospital Questionnaire is a self-rating inventory measuring aspects of six distinct categories of psychoneurosis and affective status. Considering symptoms gravity or frequency each answer is scored on a scale value (from 0 to 2 points). Category scores derive from the addition of the scores of 8 questions. Specific cut off are used to distinguish between normal and pathological behavior (anxiety 5, phobia 5, obsession 7, somatization 5, depression 4 and hysteria 4). |
baseline
|
Sleep disturbances
Time Frame: baseline
|
Sleep disturbances will be evaluated by The Pittsburgh Sleep Quality Index (PSQI).
This questionnaire contains 19 self-related questions which are combined to create 7 component scores with a range of 0-3 points (0:no difficulty, 3: severe difficulty).
Global score is the result to the addition of all component scores with a range of 0-21 points (0:no difficulty, 21: severe difficulty).
|
baseline
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EMPATHY
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypoparathyroidism
-
Peking UniversityPeking Union Medical College Hospital; First Affiliated Hospital, Sun Yat-Sen... and other collaboratorsCompletedChronic HypoparathyroidismChina
-
ShireCompletedA Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in HypoparathyroidismHypoparathyroidism | Chronic HypoparathyroidismUnited States
-
Hospital Italiano de Buenos AiresUnknownTransient HypoparathyroidismArgentina
-
Riphah International UniversityCompletedPost-Thyroidectomy HypoparathyroidismPakistan
-
Nantes University HospitalFondation SantéDige; Association Francophone de Chirurgie Endocrinienne (AFCE)RecruitingHypoparathyroidism Postprocedural | ThyroidectomyFrance
-
Institute of Biophysics and Cell Engineering of...Belarusian State Medical UniversityNot yet recruitingPostoperative Hypoparathyroidism
-
Odense University HospitalActive, not recruitingHypoparathyroidism PostproceduralDenmark
-
ShireWithdrawnChronic HypoparathyroidismJapan
-
Amolyt PharmaRecruitingEndocrine System Diseases | Parathyroid Diseases | Chronic HypoparathyroidismGermany, United States, Spain, Italy, Denmark, United Kingdom, Hungary, France, Netherlands, Canada, Portugal, Poland
-
Amolyt PharmaCompletedChronic HypoparathyroidismHungary, Netherlands